Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients

Apr 18, 2020The Journal of clinical endocrinology and metabolism

How Well Dulaglutide Works in Everyday Use and in Special Groups of People with Type 2 Diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg in 1,307 patients over 30 months.

Dulaglutide was initiated by 2,084 patients, with 15.3% switching from another GLP-1 receptor agonist.
Significant HbA1c reduction was observed across all patient subgroups, including those aged ≥ 75 years and those with chronic kidney disease.
Body weight decreased in all subgroups, with more significant reductions noted at the 1.5-mg dose compared to the 0.75-mg dose.
The treatment showed more pronounced effects in patients who were naive to GLP-1 receptor agonists and those with a shorter duration of diabetes.
Overall effectiveness of dulaglutide was consistent even in patients typically underrepresented in randomized controlled trials.

AI simplified

CONTEXT: In randomized controlled trials (RCTs) on type 2 diabetes (T2D) patients, the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-RA) dulaglutide reduced HbA1c and body weight, but generalizability of such findings to real-world T2D patients is challenging.

OBJECTIVE: We evaluated effectiveness of dulaglutide in routine clinical practice, especially in subgroups of patient that are underrepresented in RCTs.

DESIGN: Retrospective multicenter study.

SETTING: Diabetes outpatient clinics.

PATIENTS AND INTERVENTION: All consecutive patients who initiated dulaglutide between 2015 and 2018.

MAIN OUTCOME MEASURES: Changes in HbA1c and body weight were assessed up to 30 months after baseline. Effectiveness was analyzed in patient subgroups according to: prior use of GLP-1RA, persistence on treatment and dose, age, sex, disease duration, renal function, obesity, cardiovascular disease, or concomitant use of insulin or sulphonylurea.

RESULTS: From a background population of 83,116 patients, 2084 initiated dulaglutide (15.3% switching from another GLP-1RA), 1307 of whom had at least 1 follow-up visit. Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation. These effects were more pronounced in GLP-1RA-naïve patients and in those with shorter disease duration. Improvement in HbA1c was highly significant and consistent across all subgroups, including those aged ≥ 75 years, nonobese, or with chronic kidney disease. Body weight declined in all subgroups and significantly more with the 1.5-mg versus 0.75-mg dose.

CONCLUSIONS: In real-world T2D patients, effectiveness of dulaglutide on HbA1c and body weight reduction was highly consistent and significant even in subgroups of patients poorly represented in RCTs.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief